NCT04003857View on ClinicalTrials.gov

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Bronchopulmonary DysplasiaBPD
Interventions
BIOLOGICAL

PNEUMOSTEM®

A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)

BIOLOGICAL

normal saline

A single intratracheal administration of normal saline

Trial Locations (2)

Unknown

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Medipost Co Ltd.

INDUSTRY